ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication.
There is growing interest in defining biomarkers that could predict response to different chemotherapeutic agents. Excision repair cross complement 1 (ERCC1) enzyme has been shown to predict benefit of cisplatin in different types of cancer. As cisplatin-based regimens are frequently used in the salvage treatment of diffuse large B-cell lymphomas (DLBCL), a small pilot study was conducted to determine whether ERCC1 is expressed in this disease or not. Out of seven patients examined, only one had a 25% ERCC1 expression, which could represent a tumour truly expressing this marker. However, expression was not able to predict response to treatment. It remains unclear whether ERCC1 could serve as a predictive marker for cisplatin in this disease requiring further studies. Key Words : ERCC1 -Large B-cell lymphoma -Cisplatin resistance.
Azim
Hatem A
HA
The Departments of Medicine, Division of Haematology-Oncology, European Institute of Oncology, Milan, Italy; Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt and Pathology, European Institute of Oncology, Milan, Italy.
Pruneri
Giancarlo
G
Raviele
Paola R
PR
Steffanoni
Sara
S
Martinelli
Giovanni
G
Peccatori
Fedro A
FA